Daesung Microbiological Labs. Co., Ltd. (KOSDAQ: 036480)
South Korea
· Delayed Price · Currency is KRW 9,150.00
-260.00 (-2.76%)
Dec 20, 2024, 3:00 PM KST
Daesung Microbiological Labs. Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 24,164 | 25,562 | 25,500 | 23,997 | 24,801 | 25,134 | Upgrade
|
| Other Revenue | -0 | -0 | -0 | -0 | - | - | Upgrade
|
| Revenue | 24,164 | 25,562 | 25,500 | 23,997 | 24,801 | 25,134 | Upgrade
|
| Revenue Growth (YoY) | -5.25% | 0.24% | 6.26% | -3.24% | -1.32% | 0.15% | Upgrade
|
| Cost of Revenue | 21,286 | 20,857 | 20,855 | 18,404 | 16,903 | 16,846 | Upgrade
|
| Gross Profit | 2,878 | 4,705 | 4,645 | 5,593 | 7,898 | 8,288 | Upgrade
|
| Selling, General & Admin | 4,689 | 4,789 | 4,354 | 4,694 | 5,081 | 4,314 | Upgrade
|
| Other Operating Expenses | 86.31 | 87.27 | 82.98 | 122.37 | 114.9 | 99.6 | Upgrade
|
| Operating Expenses | 5,302 | 5,394 | 4,973 | 5,256 | 5,980 | 4,908 | Upgrade
|
| Operating Income | -2,424 | -689.01 | -327.52 | 337.11 | 1,918 | 3,380 | Upgrade
|
| Interest Expense | -920.1 | -892.67 | -512.58 | -277.53 | -11.19 | -14.78 | Upgrade
|
| Interest & Investment Income | 317.33 | 374.42 | 213.88 | 119.03 | 152.32 | 210.57 | Upgrade
|
| Earnings From Equity Investments | -40.86 | 36.39 | -14.6 | -4.97 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -59.51 | 58.67 | 478.31 | 566.84 | -443.49 | 141.37 | Upgrade
|
| Other Non Operating Income (Expenses) | 93.85 | 30.83 | 205.01 | 95.4 | -97.95 | -916.55 | Upgrade
|
| EBT Excluding Unusual Items | -3,033 | -1,081 | 42.49 | 835.87 | 1,517 | 2,801 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.19 | -0.29 | -0.91 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 9.44 | -0.07 | 2,219 | 7 | 11.72 | 11.71 | Upgrade
|
| Pretax Income | -3,024 | -1,082 | 2,261 | 842.87 | 1,529 | 2,813 | Upgrade
|
| Income Tax Expense | -224.81 | -402.05 | 557.38 | -23.05 | 10.55 | 341.6 | Upgrade
|
| Net Income | -2,799 | -679.68 | 1,703 | 865.92 | 1,519 | 2,471 | Upgrade
|
| Net Income to Common | -2,799 | -679.68 | 1,703 | 865.92 | 1,519 | 2,471 | Upgrade
|
| Net Income Growth | - | - | 96.69% | -42.98% | -38.54% | -22.05% | Upgrade
|
| Shares Outstanding (Basic) | 4 | 4 | 4 | 4 | 4 | 4 | Upgrade
|
| Shares Outstanding (Diluted) | 4 | 4 | 4 | 4 | 4 | 4 | Upgrade
|
| Shares Change (YoY) | 0.25% | -0.05% | -0.34% | 0.47% | -0.13% | 0.02% | Upgrade
|
| EPS (Basic) | -736.04 | -178.86 | 448.00 | 227.00 | 400.00 | 650.00 | Upgrade
|
| EPS (Diluted) | -736.04 | -178.86 | 448.00 | 227.00 | 400.00 | 650.00 | Upgrade
|
| EPS Growth | - | - | 97.36% | -43.25% | -38.46% | -22.06% | Upgrade
|
| Free Cash Flow | 480.32 | -2,490 | -1,160 | -764.71 | -10,770 | -9,123 | Upgrade
|
| Free Cash Flow Per Share | 126.29 | -655.25 | -305.03 | -200.47 | -2836.73 | -2399.78 | Upgrade
|
| Gross Margin | 11.91% | 18.41% | 18.22% | 23.31% | 31.85% | 32.98% | Upgrade
|
| Operating Margin | -10.03% | -2.70% | -1.28% | 1.40% | 7.73% | 13.45% | Upgrade
|
| Profit Margin | -11.58% | -2.66% | 6.68% | 3.61% | 6.12% | 9.83% | Upgrade
|
| Free Cash Flow Margin | 1.99% | -9.74% | -4.55% | -3.19% | -43.43% | -36.30% | Upgrade
|
| EBITDA | 431.33 | 2,173 | 2,378 | 2,875 | 3,865 | 4,490 | Upgrade
|
| EBITDA Margin | 1.78% | 8.50% | 9.33% | 11.98% | 15.59% | 17.86% | Upgrade
|
| D&A For EBITDA | 2,855 | 2,862 | 2,706 | 2,538 | 1,948 | 1,110 | Upgrade
|
| EBIT | -2,424 | -689.01 | -327.52 | 337.11 | 1,918 | 3,380 | Upgrade
|
| EBIT Margin | -10.03% | -2.70% | -1.28% | 1.40% | 7.73% | 13.45% | Upgrade
|
| Effective Tax Rate | - | - | 24.66% | - | 0.69% | 12.14% | Upgrade
|
| Advertising Expenses | - | 176.8 | 51.04 | 122.44 | 93.24 | 60.12 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.